Innovation Pharmaceuticals Inc (IPIX)

[Fletch]

Poster conclusions section.......really like the bold one below,
Fletch

Conclusions
• p53 induction by Kevetrin is non-genotoxic
• Tumors harboring both mutant and wild type p53 can be treated with Kevetrin
• Kevetrin induced apoptotic cell death in wild type p53 and mutant p53 cells through
p53 apoptotic pathways
• Kevetrin stabilized p53 and induced p53 transcriptional targets in wild type p53
• Inhibition of MDM2 by Kevetrin induces transcriptional independent apoptosis
• Kevetrin induced degradation of mutant p53 mediated by reactivation of
MDM2 E3 ligase
• Kevetrin is a potent anti-tumor agent
• Expression of p21 in lymphocytes is a biomarker for Kevetrin
• Kevetrin is in a Phase 1 clinical trial; 3 cohorts have been completed without DLT